EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effect of a High‐Fat Meal on the Pharmacokinetics of an Immediate Release Atogepant Tablet

Ramesh R Boinpally, Joel M Trugman

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1451 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Ramesh R Boinpally und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie, North Chicago, IL, USA. Hauptthemen laut MEDLINE: Cross-Over Studies, Food-Drug Interactions, Tablets, Area Under Curve. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atogepant, an oral calcitonin gene‐related peptide receptor antagonist, is approved for the preventive treatment of migraine. A phase 1, open‐label, single‐dose, 2‐period crossover study evaluated the effect of a high‐fat meal on the pharmacokinetics and safety of atogepant in 20 healthy adults. Administration of atogepant 60 mg immediate‐release (IR) tablets under fed conditions reduced the area under the plasma concentration‐time curve (AUC) from 0 to time t and from 0 to time infinity by approximately 18% and reduced the maximum plasma concentration (C max ) by 22%. The 90% confidence intervals for the geometric mean ratios of C max and AUC were not contained within the bioequivalence limits of 80%‐125%. There was no change in the median time to maximum plasma concentration in the fed versus fasted state. The incidence of treatment‐emergent adverse events (TEAEs) was similar between fed and fasted conditions. Four TEAEs were considered related to study intervention and were reported after participants received atogepant under fasted conditions (3 participants). A single‐dose atogepant 60 mg IR tablet was safe and tolerated under both fed and fasted states. Due to the wide effective dose range of 10‐60 mg/day for atogepant for the preventive treatment of migraine, the food effect on its pharmacokinetics is not considered clinically relevant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cross-Over StudiesFood-Drug InteractionsTabletsArea Under CurveFastingHumansMaleAdultFemaleYoung AdultCalcitonin Gene-Related Peptide Receptor AntagonistsAdministration, OralMiddle AgedTherapeutic EquivalencyDietary FatsDiet, High-FatMigraine DisordersHealthy Volunteers

Stichwörter der Autor:innen

CGRP receptor antagonistatogepantfood effectimmediate releasemigraine

Substanzen

TabletsCalcitonin Gene-Related Peptide Receptor AntagonistsDietary Fats

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie, North Chicago, IL, USA.

Zitieren

APA

Boinpally, R. R., & Trugman, J. M. (2024). Effect of a High‐Fat Meal on the Pharmacokinetics of an Immediate Release Atogepant Tablet. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1451

Vancouver

Boinpally RR, Trugman JM. Effect of a High‐Fat Meal on the Pharmacokinetics of an Immediate Release Atogepant Tablet. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1451

BibTeX
@article{Boinpally2024,
  author = {Boinpally, Ramesh R and Trugman, Joel M},
  title = {Effect of a High‐Fat Meal on the Pharmacokinetics of an Immediate Release Atogepant Tablet},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1451}
}
Kostenlos starten →